Australia Iron Deficiency Anemia Therapy Market is expected to grow with the CAGR of 8.9% in the forecast period of 2021 to 2028. The years considered for the study are as mentioned below.
Access Full Report @ https://www.databridgemarketresearch.com/zh/reports/australia-iron-deficiency-anemia-therapy-market
Australia iron deficiency anemia therapy market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenarios.
The major players dealing in Australia iron deficiency anemia therapy market are introducing a strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award, and recognition into the market. This helped companies to maximize sales with an enhanced product portfolio.
For instance:
- In April 2021, Sanofi announced that it made the successful acquisition of Kiadis, which is a clinical-stage biopharmaceutical company. This acquisition enhanced the company's treatment strategies, thereby improving the company's overall revenue in the market
Sanofi is the dominating player in Australia iron deficiency anemia therapy market. The other key players existing in the market are Pfizer Ltd., Merck KGaA, and Vifor Pharma Pty Ltd., GlaxoSmithKline plc, SHIELD THERAPEUTICS, Aspen Pharmacare Australia Pty Ltd., PHARMACOSMOS A/S, BLACKMORES, and AFT Pharmaceuticals, among others.
Sanofi.
Sanofi, founded in the year 2004, is headquartered in Paris, France. The company is focused on improving access to healthcare and supporting people by providing scientific innovation into healthcare solutions, rare diseases, and more. The company has business segments like pharmaceuticals, consumer healthcare, and vaccines, and pharmaceuticals are the market-focused segment. The company has several product categories, which are prescription products, vaccines, OTC products, generics, patient services, resources for health providers, and among more in which Prescription Products is the market-focused category.
The company has a presence across Asia-Pacific, Europe, South America, North America, and the Middle East, and Africa.
The company also has various subsidiary companies, including Avertis Inc. (US), Genzyme Corporation (US), Genzyme Europe BV (Netherlands), Hoechst GmbH (Germany), among others.
- In April, Sanofi announced that it successfully acquired Kymab Group Ltd. This acquisition helped in building on the company's presence in immunology treatments. This is anticipated to improve the company's global position and increase market revenue in the future
- In September 2020, Sanofi announced that it acquired Principia Biopharma Inc. This acquisition has strengthened the company's product portfolio and is anticipated to improve the overall revenue and market revenue in the future
Merck KGaA
Merck KGaA headquarter is in Darmstadt, Germany, and was founded in the year 1668. The company is engaged in providing solutions in the field of healthcare, life science, and performance materials with a passion for technology and love for science. The company has many business segments like healthcare, life science, performance materials, and healthcare is the market-focused segment. The company has several product names including Iron–Dextran, Ferrous gluconate, Ferrous Fumarate, Iron(II) fumarate, Ferric citrate, Ferric ammonium citrate, among others in which Iron–Dextran, Ferrous gluconate, Ferrous Fumarate, Iron(II) fumarate, Ferric citrate, Ferric ammonium citrate is the market-focused category.
For instance,
- In July 2018, Merck KGaA signed an agreement with InnoCore Pharmaceuticals to develop an innovative product or a new platform for the development of sustained-release biological API. The agreement includes InnoCore Pharmaceuticals drug delivery technology that is SynBiosys, which will be used for the delivery of large molecules APIs such as proteins and peptides. This agreement helped the company to enhance its product portfolio in terms of technological use for the delivery of API
The company has a wide presence across Africa, Asia, Europe, Latin America, North America, Oceania. The company also has various subsidiary companies, including Sigma-Aldrich (OM) Ltd. (Greece), Merck Foundation GmbH (Germany), Merck S.A. (Venezuela), iOnctura SA (Switzerland), Merck Ltd. (UK), Fluka Chemical Corp. (US), among others.
Pfizer Ltd.,
Pfizer Ltd., headquartered in New York, U.S., was incorporated in the year 1849. The company focused on providing a standard for quality, safety, and value in the discovery, development, and manufacturing of health care products, including innovative medicines and vaccines. The company has many business segments such as Healthcare, Life Science, Performance Materials, and Biopharma is the market-focused segment. The company has several product names which are Accupril, Accuretic, Aciclovir Intravenous Infusion, Adriamycin, Alcohol, Aldactone, Apomine, Aricept, Macrodantin, Merrem, Methoblastin, Methotrexate Injection, Metoclopramide, Midazolam Injection, Minidiab, Minipress, Minulet, Monofeme, Monofer, among others in which Monofer is the market focused category.
- In November 2019, Pfizer, Inc. announced that its division named Upjohn is combined with Mylan NV and formed a new company named Viatris. This combination of the company's business division with Mylan NV has increased its product portfolio, leading to increased demand for its product in the market
The company has a presence across North America, Europe, Middle East, and Africa, Asia-Pacific, and South America. The company also has various subsidiary companies, including Pfizer Animal Health BV ( the Netherlands), Pfizer Asia International BV (Netherlands), Pfizer Australia Superannuation Pty Ltd ( Australia), Pfizer Dominicana, SA (Dominican Republic), and Pfizer Egypt SAE (Egypt) among others.
